Oncolytics Biotech (TSE:ONC) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Oncolytics Biotech Inc. reports a net loss of $6,894 thousand for Q1 2024, a slight increase from $6,437 thousand in the same period last year. The company’s total assets decreased to $34,750 thousand as of March 31, 2024, from $38,820 thousand at the end of 2023, with a reduced cash position from $34,912 thousand to $29,603 thousand. Shareholders’ equity also saw a decline, dropping from $27,563 thousand to $22,969 thousand in the first quarter.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue